Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial

Journal of the American Academy of Dermatology

Volumn 76, Issue 1, 2017, Pages 70-80

  Gottlieb, Alice ^a   Sullivan, John ^b   van Doorn, Martijn ^c   Kubanov, Alexey ^d   You, Ruquan ^e   Parneix, Anne ^f   Hugot, Sophie ^f   Milutinovic, Marina ^f  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Holdsworth House Medical Practice   (Australia)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology   (Russian Federation)

^e Beijing Novartis Pharma Co Ltd   (China)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

clear or almost clear skin; clinical trial; palmoplantar psoriasis; quality of life; secukinumab; superiority

Indexed keywords

PLACEBO; SECUKINUMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOT PAIN; FOOT SOLE; FUNCTIONAL STATUS; HAND PAIN; HAND PALM; HEADACHE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PALMOPLANTAR INVESTIGATOR GLOBAL ASSESSMENT; PALMOPLANTAR PSORIASIS AREA AND SEVERITY INDEX; PALMOPLANTAR QUALITY OF LIFE INSTRUMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PUSTULOSIS PALMOPLANTARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN DISEASE ASSESSMENT; SUPERFICIAL MYCOSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; FOOT DERMATOSES; HAND DERMATOSES; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85000699704     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.07.058     Document Type: Article

References (31)

1. 1 Kumar, B., Saraswat, A., Kaur, I., Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol 82 (2002), 192–195.
2. 2 Pettey, A.A., Balkrishnan, R., Rapp, S.R., Fleischer, A.B., Feldman, S.R., Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 49 (2003), 271–275.
3. 3 Melwani, P.M., Penate, Y., Guillermo, N., Soler, E., Hernandez-Machin, B., Borrego, L., Leflunomide in the treatment of palmoplantar pustulosis. Arch Dermatol 145 (2009), 1224–1226.
4. 4 Elahmed, H.H., Rapid improvement of palmoplantar psoriasis after cessation of smoking. Sultan Qaboos Univ Med J 13 (2013), 188–189.
5. 5 Chung, J., Callis Duffin, K., Takeshita, J., et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol 71 (2014), 623–632.
6. 6 Van Voorhees A, Feldman SR, Koo JKM, Lebwohl MG, Menter A. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management option. Available at: https://www.psoriasis.org/sites/default/files/accessing-health-care/FY10_Pocket_Guide_WEB.pdf/. Accessed September 22, 2016.
7. 7 Au, S.C., Madani, A., Alhaddad, M., Alkofide, M., Gottlieb, A.B., Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. J Drugs Dermatol 12 (2013), 861–866.
8. 8 Gelfand, J.M., Wan, J., Callis Duffin, K., et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol 148 (2012), 487–494.
9. 9 Takahashi, H., Iinuma, S., Tsuji, H., Honma, M., Iizuka, H., Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients. J Dermatol 41 (2014), 686–689.
10. 10 Frankel, A.J., Goldenberg, G., Insights into treating palmoplantar psoriasis. Skin and Aging, 18, 2010.
11. 11 Strober, B.E., Griffiths, C.E., O'Dell, S.J., Tebbey, P.W., Barker, J.N., International Psoriasis, C., Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. Br J Dermatol 174 (2016), 212–215.
12. 12 Bissonnette, R., Poulin, Y., Guenther, L., Lynde, C.W., Bolduc, C., Nigen, S., Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 25 (2011), 1402–1408.
13. 13 Leonardi, C., Langley, R.G., Papp, K., et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 147 (2011), 429–436.
14. 14 Au, S.C., Goldminz, A.M., Kim, N., et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat 24 (2013), 179–187.
15. 15 Robert Bissonnette; Jennifer Cather; Phoebe Rich; Alan Menter; Carlos Ferrandiz; Mark Goodfield; ChiaChi Hu ERMDMS. Efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for palmoplantar psoriasis in patients with moderate to severe plaque psoriasis in phase 2 and phase 3 (ESTEEM) trials. 73rd Annual Meeting of the American Academy of Dermatology. San Francisco, CA 2015.
16. 16 Hueber, W., Patel, D.D., Dryja, T., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med, 2, 2010, 52ra72.
17. 17 Ivanov, S., Linden, A., Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 30 (2009), 95–103.
18. 18 Papp, K.A., Langley, R.G., Sigurgeirsson, B., et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168 (2013), 412–421.
19. 19 Rich, P., Sigurgeirsson, B., Thaci, D., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168 (2013), 402–411.
20. 20 Langley, R.G., Elewski, B.E., Lebwohl, M., et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371 (2014), 326–338.
21. 21 Paul, C., Lacour, J.P., Tedremets, L., et al. Efficacy, safety, and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 29 (2015), 1082–1090.
22. 22 Pariser, D.M., Bagel, J., Gelfand, J.M., et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 143 (2007), 239–242.
23. 23 Thaci, D., Blauvelt, A., Reich, K., et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73 (2015), 400–409.
24. 24 Paul, C., Reich, K., Gottlieb, A.B., et al. Secukinumab improves hand, foot, and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol 28 (2014), 1670–1675.
25. 25 Langley, R.G., Feldman, S.R., Nyirady, J., van de Kerkhof, P., Papavassilis, C., The 5-point Investigator's Global Assessment (IGA) Scale: aA modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 26 (2015), 23–31.
26. 26 Fredriksson, T., Pettersson, U., Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157 (1978), 238–244.
27. 27 Weisman, S., Pollack, C.R., Gottschalk, R.W., Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 14 (2003), 158–165.
28. 28 Finlay, A.Y., Khan, G.K., Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994), 210–216.
29. 29 Farley, E., Masrour, S., McKey, J., Menter, A., Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 60 (2009), 1024–1031.
30. 30 Brooks, R., EuroQol: the current state of play. Health Policy 37 (1996), 53–72.
31. 31 EuroQol, G., EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.